Terumo introduces new radial to peripheral devices at TCT 2019


radialTerumo Medical have announced that it has introduced the Radial to Peripheral (R2P) MISAGO RX self-expanding peripheral stent at the 31st Transcatheter Cardiovascular Therapeutics (TCT) conference (25–29 September, San Francisco, USA). The introduction of R2P MISAGO helps physicians bring the benefits associated with a radial access approach to patients with peripheral arterial disease (PAD).

According to the US Centers for Disease Control and Prevention (CDC), PAD affects approximately 8.5 million people in the USA, and is characterised by a narrowing or blockage of arteries limiting blood flow to the lower extremities; an endovascular approach is often used for treatment.

R2P MISAGO is a device within the R2P portfolio, the first and only portfolio of longer-length radial devices specifically designed for peripheral procedures. R2P MISAGO is the longest stent platform specifically designed for above-the-knee PAD interventions via radial access, incorporating Rapid Exchange (RX) technology and innovative bare metal stent design.

The launch of R2P MISAGO is complemented by the introduction of R2P CROSSTELLA RX PTA balloon dilatation catheter, the longest 0.018″ balloon designed for use in radial to peripheral procedures. Both R2P MISAGO and R2P CROSSTELLA have a 200 cm working length, enabling physicians to perform more peripheral procedures for more patients.

“As the industry leader in radial access, Terumo is very proud of the work we have done in partnership with the medical community to drive utilisation of radial procedures,” says Chris Pearson, Executive Vice President, Commercial Operations, Terumo Interventional Systems. “The launch of these additional devices enhances our existing R2P portfolio, and underscores Terumo’s commitment to developing new, innovative technology to advance peripheral vascular care.”

“Using radial artery access is associated with quicker ambulation, improved patient comfort, and satisfaction. Terumo’s introduction of R2P MISAGO and R2P CROSSTELLA as part of the R2P portfolio provides physicians with additional options to treat PAD patients from the wrist,” comments John Coppola (NYU Langone Medical Center, New York, USA).

R2P MISAGO is currently in a limited market release within the USA, and will have full commercial availability in October 2019. R2P CROSSTELLA is currently commercially available as part of the R2P portfolio of radial length devices.


Please enter your comment!
Please enter your name here